Mylotarg (gemtuzumab ozogamicin): Market Withdrawal
Audience: Oncology, Hematology
ISSUE: FDA notified healthcare professionals that results from a recent clinical trial raised new concerns about the product’s safety, and the drug failed to demonstrate clinical benefit to patients enrolled in…
No related posts.




facebook
rss
twitter